Overview
Saturday,August 14, 2010
Pasadena, CA
Program Director: Chandra P. Belani, MD, Miriam Beckner Distinguished Professor of Medicine, Penn State Milton S. Hershey Medical Center, Penn State College of Medicine, Deputy Director, Penn State Cancer Institute, Hershey, PA
August 14, 2010
Sheraton Pasadena,
303 Cordova Street,
Pasadena,
CA 91101,
Phone: (626) 449-4000
Jointly sponsored by:A. Webb Roberts Center for Continuing Medical Education of Baylor Health Care System, International Cancer Network, and Camenae Group, Inc
Educational Grants
This activity is supported by education grants from:
Genentech BioOncology
Lilly USA, LLC
Target Audience
This symposium is directed primarily to medical oncologists, radiation oncologists, surgical oncologists, pharmacists, and registered oncology nurses interested in new developments for treatment of lung cancer and head & neck cancer. No specific skill or knowledge other than a basic training in oncology is required for successful participation in this activity. Fellows are also invited to attend.
Statement of Need/Program Overview
This program is intended to facilitate interaction among oncologists and nurses interested in development of novel therapeutics for treatment of lung cancer and head & neck cancer. In addition to multimodality therapy, adjuvant therapy, this symposium will present data of most promising emerging agents currently in development for the treatment of lung cancer and head & neck cancer. There will be in-depth discussion of both antiangiogenic agents and inhibitors of EGFR pathways. Drugs that target multiple signaling pathways will also be given significant focus.
LEARNING OBJECTIVES
After completing this activity, the participant should be better able to:
- Describe the current status of chemotherapy, radiation therapy, and state-of-the-art therapies of lung cancer
- Define the current status of multimodality therapy in the treatment of localized and advance lung cancer
- Outline the clinical data supporting the optimal use of EGFR inhibitors in the treatment of lung cancer
- Identify agents that target angiogenesis, including the safety profile and efficacy
- Specify the impact of current strategies in the treatment of head & neck cancer
- Identify the role of maintenance therapy in the lung cancer
- Describe novel therapeutic agents that potentially improve upon standard chemotherapeutics
Registration Fee
Registration fee partially covers continental breakfast, lunch and syllabus book
□ Physicians $100.00
□ Nurses, Pharmacists, others $50.00
□ Fellows $50.00
□ *Industry $350.00
Payment may be made: □ MC □ Visa □ Discover □ Amex □ Check
Credit Card Number___________________________ Expiration Date_______________
Name as it appears on Credit Card____________________________________________
________________________________________________________________________
________________________________________________________________________
Signature________________________________________________________________
Register online at www.Internationalcancernetwork.com
Please make checks payable to International Cancer Network. . Mail checks to 860 Hebron Pkwy, Ste 1104, Lewisville, TX 75057
To reserve your place for the meeting, please complete the registration form and fax it 443-267-0016. If you have any questions please call 972-939-6206 or E-mail: knaidu@internationalcancernetwork.com
Physician Continuing Education
Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of A. Webb Roberts Center for Continuing Medical Education of Baylor Health Care System and International Cancer Network. A. Webb Roberts Center for Continuing Medical Education of Baylor Health Care System is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation
A. Webb Roberts Center for CME of Baylor Health Care System designates this educational activity for a maximum of 5.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Nursing Continuing Education
TNA/ANCC
Accreditation Statement
Camenae Group, Inc. is approved provider of continuing nursing education by the Texas Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation
This activity provides up to 5.0 Nursing Contact hours.
A statement of credit will be issued only upon receipt of a completed activity evaluation form, and will be mailed within six weeks.
Disclaimer
The information provided at this CME/CE activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition
Non-Endorsement of Products
The Camenae Group, Inc. does not imply either real or implied endorsement of any product, service, or company referred to in this educational activity.
Americans with Disabilities Act
Event staff will be glad to assist you with any special needs (ie, physical, dietary, etc). Please contact Kamatham A. Naidu, PhD prior to the live event at 972-672-7645.